Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Analysis: Fight for cheap drugs shifts from AIDS to new hepatitis pills

A new battle is looming over access to antiviral medicines in developing countries - this time for treating hepatitis C - more than a decade after a global showdown over the price of AIDS drugs in Africa.

Published
16 December 2013
From
Reuters
Why Talk Of A Hepatitis C Price War Should Act As A Warning To The Pharma Industry-At-Large

Bloomberg reporter Drew Armstrong may have broken one of the most important pharmaceutical news stories of the year on Tuesday when he revealed that a leading US pharmacy benefits manager (PBM) is to take an aggressive stance towards the pricing of new hepatitis C therapies.

Published
11 December 2013
From
Forbes
Express Scripts Pushes Price Competition for Gilead Drug

The biggest U.S. drug benefits manager plans to start a price war over a new generation of hepatitis C treatments that will cost $1,000 a pill, in a bid to drive down spending on the medicines.

Published
11 December 2013
From
Bloomberg
AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C

In the 394-patient SAPPHIRE-II study, 96 percent of patients who previously failed pegylated interferon and ribavirin treatment, including approximately 49 percent of who were prior null responders, achieved sustained virologic response at 12 weeks (SVR(12) ) with the regimen. The majority of patients were GT1a, considered a difficult-to-treat subtype, and the SVR(12) rates of GT1a and GT1b were 96 percent and 97 percent, respectively.

Published
10 December 2013
From
AbbVie press release
Activists Condemn Gilead for Exorbitant Price of Their New Hepatitis C Drug

The Fair Pricing Coalition (FPC) today condemned Gilead Sciences for the price set for its direct acting antiviral (DAA) Sovaldi™ (sofosbuvir) - $84,000 for a 12-week course.

Published
10 December 2013
From
Fair Pricing Coalition / The Body
Beyond the Hype: What Sofosbuvir Means—and Doesn’t—for Global Hepatitis C Treatment

In this new report, Beyond the Hype: What Sofosbuvir Means—And Doesn’t—For Global Hepatitis C Treatment, we examine the new hepatitis C treatment market and projected revenues, and look back at what we can learn from the fight for access to HIV medicines in the 2000s to help secure reductions in the price of these promising new hepatitis C treatments.

Published
10 December 2013
From
Open Society Foundation
US FDA approves Gilead's $1000-a-day hepatitis C pill

Most patients will be treated with the $1,000-a-day drug for 12 weeks, resulting in a total list price of $84,000, according to Gilead spokeswoman Cara Miller.

Published
08 December 2013
From
Reuters
FDA approves Sovaldi for chronic hepatitis C

The U.S. Food and Drug Administration today approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection. Sovaldi is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon.

Published
08 December 2013
From
US FDA
Sofosbuvir for Hepatitis C: Simpler, Shorter, Safer?

The availability of these agents will provide unprecedented opportunities for off-label use of these therapies in many patients, including those with decompensated cirrhosis or chronic kidney disease, pediatric populations, and those with HIV coinfection. Because many of these populations represent relatively small numbers of patients with HCV, it may be difficult to accumulate the requisite data and possibly cost-prohibitive for manufactur

Published
04 December 2013
From
Medscape (requires registration)
Fair Pricing Coalition Disappointed by the High Price of New Janssen Hepatitis C Drug Olysio (simeprevir)

Janssen has set the wholesale acquisition cost, (WAC) for a single 12-week course of Olysio at $66,360. Though this is in parity with current HCV PIs, the FPC believes that all HCV drugs are priced too high. The WAC price of Olysio represents only part of the cost of an anti-HCV regimen, including at least $18,000 in WAC costs of interferon and ribavirin, plus the additional cost of the NS3 Q80K polymorphism screening test recommended by the FDA for all patients before initiating Olysio therapy.

Published
29 November 2013
From
Fair Pricing Coalition

Filter by country